Scarica l'app Stockscreener
255.25
0.79%
2.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand Pharmaceuticals director Jason Haas sells $1.65m stock By Investing.com - Investing.com South Africa
Ligand (LGND) director exercises options, sells 6,461 common shares around $255–$256 - Stock Titan
Kozarich Sells Shares of Ligand Pharmaceuticals - Intellectia AI
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? - Yahoo Finance
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Ligand Pharmaceuticals Stock 9-Day Winning Spree: Stock Climbs 11% - Trefis
Ligand Pharmaceuticals Stock Rockets 11% With 9-Day Winning Streak - Trefis
Insider Sell: John Lamattina Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus
Ligand Pharma director John L. LaMattina sells $1.15 million stock - Investing.com
Ligand Pharmaceuticals director Jason Aryeh sells $1.25m in stock By Investing.com - Investing.com India
Ligand Pharmaceuticals director Jason Aryeh sells $1.25m in stock - Investing.com UK
Ligand Pharmaceuticals Director Sold Shares Worth Over $1.1M - TradingView
Director-linked funds trim Ligand (LGND) stake with 5,000-share sale - Stock Titan
Director sells 4,591 Ligand (LGND) shares in multiple open-market trades - Stock Titan
LGND (NASDAQ) Form 144 shows 4,000-share option exercise and restricted stock notices - Stock Titan
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date - Benzinga
JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo - Stock Titan
Ligand Pharmaceuticals Incorporated $LGND Shares Purchased by GW&K Investment Management LLC - MarketBeat
Franklin Resources Inc. Acquires 266,304 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $254.46 By Investing.com - Investing.com Nigeria
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand Pharmaceuticals stock hits 52-week high at $254.46 - Investing.com
Ligand Pharmaceuticals to hold Investor Day in NYC on Dec 8, 2026, sharing strategy and financial outlook. - Pluang
Ligand Announces 2026 Investor Day in New York City - The Manila Times
Los Angeles Capital Management LLC Boosts Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
BNP Paribas Financial Markets Buys 30,865 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition - Stock Titan
Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants - Stock Titan
Director John L. Lamattina receives LGND (LGND) RSUs and stock options - Stock Titan
Ligand (LGND) director John Kozarich receives RSUs and stock options grant - Stock Titan
Ligand (NASDAQ: LGND) director Jason Haas receives RSU and option grants - Stock Titan
Ligand (LGND) director Nancy Ryan Gray receives new RSUs and options - Stock Titan
Ligand Pharma Shareholders Back Governance and Incentive Plan - TipRanks
Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan - Stock Titan
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million - AOL.com
Cibc World Market Inc. Has $4.85 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Bank of America Securities Remains a Buy on Ligand Pharma (LGND) - The Globe and Mail
Ligand Pharmaceuticals Insider Sold Shares Worth $1,135,316, According to a Recent SEC Filing - Moomoo
Ligand Pharmaceuticals CLO Reardon sells $1.1 million in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1.1 million in stock - Investing.com
Ligand (NASDAQ: LGND) CLO sells 5,000 shares, exercises options - Stock Titan
Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote - Bez Kabli
Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) - TMX Newsfile
Legend Bio rises after early-stage data for in vivo CAR-T therapy - Seeking Alpha
How The Ligand Pharmaceuticals (LGND) Investment Story Is Evolving Without Fresh Analyst Targets - Yahoo Finance
Free float of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Number of shareholders of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Future Fund LLC Purchases Shares of 9,280 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Insider Unloading: Octavio Espinoza Sells Options, Realizes $307K - Benzinga
Ligand Pharma (LGND) Receives a Buy from Bank of America Securities - The Globe and Mail
Ligand (NASDAQ: LGND) CFO exercises 1,736 stock options, now holds 27,679 shares - Stock Titan
BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $266 - Moomoo
Ligand to Participate in June Investor Conferences - marketscreener.com
Ligand executives head to Goldman Sachs, Stifel investor events in June - Stock Titan
LGND Q1 2026 Earnings: Earnings Miss Weighed Against Upbeat Strategic ProgressLow Growth Earnings - newsline.com
Ligand Pharmaceuticals Bets Big on Royalty Growth - TipRanks
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):